
DFTX Stock Forecast & Price Target
DFTX Analyst Ratings
Bulls say
Definium Therapeutics is currently rated as a Buy due to four key factors. Firstly, its candidate DT120 ODT has a high probability of success in GAD, with Phase 3 data expected in early 2026. Second, GAD presents a large market opportunity for DT120, with potential for multi-billion dollar revenues. Third, recent data for DT120 in MDD showed impressive durability, setting it apart from other treatments. Finally, while DFTX has a higher market cap compared to other psychedelic companies, the space as a whole is undervalued, and DFTX is poised to be one of the leaders in this market. The company's DCF analysis gives a target price of $60, using a 10% discount rate and 0% terminal growth rate. The current offering has resulted in a slight decrease in the price target to $58, but the model still assumes a 65% probability of approval for MDD and 55% for GAD, which are reasonable given the positive data from the trials. DT120's profile, with less frequent dosing and strong efficacy, is expected to drive significant demand in the anxiety market, which has a high unmet need. Additionally, the company has other pipeline programs, such as DT402 for autism spectrum disorder
Bears say
Definium Therapeutics is facing significant risks in developing its products for neurological and psychiatric disorders, as trials can fail for various reasons and the safety and efficacy of its LSD D-tartrate orally disintegrating tablet/ODT, DT120, is yet to be fully established. Additionally, the company's approach may not be successful in producing the intended results, and regulatory bodies may not approve its products. There are also challenges related to achieving blinding in clinical trials for psychedelic products and potential difficulties in defending their intellectual property. Moreover, negative market perception and potential reimbursement-related challenges may hinder the company's success.
This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DFTX Analyst Forecast & Price Prediction
Start investing in DFTX
Order type
Buy in
Order amount
Est. shares
0 shares